We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Harbor Multi asset Explorer ETF | AMEX:MAPP | AMEX | Exchange Traded Fund |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.1463 | -0.66% | 22.053 | 0 | 21:15:02 |
From Jun 2019 to Jun 2024
AstraZeneca PLC (AZN), a major international healthcare business, said Thursday it has terminated the license agreement with MAP Pharmaceuticals Inc (MAPP), regarding Unit Dose Budesonide, or UDB adding that it expects to record an impairment charge of $44 million in the second quarter results.
MAIN FACTS:
-UDB, an investigational treatment for paediatric asthma, was the subject of an initial Phase III clinical trial conducted by MAP Pharmaceuticals.
-On Feb. 23, MAP announced that the trial failed to meet its primary endpoints.
-In light of the clinical trial results, AstraZeneca exercised its right to terminate the license agreement.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
1 Year Harbor Multi asset Explo... Chart |
1 Month Harbor Multi asset Explo... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
